Nevertheless, 20% of BRCA1/2-mutated ovarian malignancies do not respond to PARPi [20–23], highlighting the urgent need for new treatment approaches for inherently or acquired resistant tumours. This evidence concerns the gene BRCA1 and neoplasm.